drugset / Trial / NCT07148557
A Study of Single Dose of LP-003 in Adolescent Subjects
Non-randomizedSequentialOpen-labelTreatment
Summary
This is a single-center, open-label, phase Ib clinical study to evaluate the safety, pharmacokinetics and pharmacodynamic characteristics of LP-003 injection in adolescent subjects aged 12-18 years.
Timeline
- Start
- 2025-10-01
- Primary completion
- 2026-05-31
- Completion
- 2026-09-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | LP-003 | Unknown | 400 mg | Subcutaneous |
| Subject | LP-003 | Unknown | 600 mg | Subcutaneous |